Answers are grounded in this paper and cite their sources.
Randomized trial investigates metoclopramide's effect on pneumonia and mortality in stroke patients, suggesting potential benefits.
Background and aims Pneumonia causes more deaths than neurological damage after stroke. Stroke-associated pneumonia is caused by aspiration of vomited/regurgitated gastric content Methods We assess whether metoclopramide, an antiemetic, prevents pneumonia, reduces mortality, and improves long-term recovery. Results This is a single-blind randomised control trial. 2100 adults within 24 hours of stroke onset, moderate to severe neurological impairment (NIHSS≥10) or dysphagia and NIHSS≥6, without pneumonia at screening, contraindications to metoclopramide, pregnancy, and life-limiting comorbidities are being recruited from over 70 UK hospitals. Patients are randomised (1:1) by minimisation on age, mRS, NIHSS, type of centre and time from onset to receive 10mg of metoclopramide/placebo (normal saline 2ml) tds via injection or nasogastric tube for 14 days. Follow-up is conducted at day 14 in person and at 6-months by telephone. Conclusions The primary outcome is all-cause mortality by 6 months. Secondary outcomes include pneumonia diagnosis, number of days of antibiotic treatment, quality of life (QOL), swallow, and neurological recovery at day 14; and mRS, frailty, QOL, swallow recovery, and home time at 6-months. Conflict of interest
No takes yet. Share an insight, caveat, or question.
Roffe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: